Paul Fleming

2.5k citations

23 papers · 1.4k indexed · h-index 12

Co-authors: Lawrence R. Dick Christopher Blackburn Bing Guan Kazumi Shiosaki Paul Hales Christopher Tsu Jonathan L. Blank Khristofer Garcia
Topics: Ubiquitin and proteasome pathways (10 papers)Peptidase Inhibition and Analysis (6 papers)Cancer Treatment and Pharmacology (4 papers)
Cited by: Hematology Oncology Molecular Biology
Journals: Journal of the American Chemical Society Blood Cancer Research
Partner nations: United States Japan Norway

In The Last Decade

Paul Fleming

22 papers receiving 1.3k citations

Peers

Countries citing papers authored by Paul Fleming

Since Specialization

Citations

This map shows the geographic impact of Paul Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Fleming more than expected).

Fields of papers citing papers by Paul Fleming

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Fleming. The network helps show where Paul Fleming may publish in the future.

Co-authorship network of co-authors of Paul Fleming

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Fleming. A scholar is included among the top collaborators of Paul Fleming based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Fleming. Paul Fleming is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model 2018 ·International Immunopharmacology ·(unknown),Yusaku Komoike,Yoshiki Nakamura,Takeshi Watanabe,Masashi Yamasaki,Paul Fleming,Lili Yang,Dulce Soler,Eric R. Fedyk,Noboru Tsuchimori	25
2	Abstract 2641: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors 2016 ·Cancer Research ·Rami Rahal,Erica N Evans,Wei Hu,Michelle Maynard,Paul Fleming,Lucian DiPietro,Joseph L. Kim,Michael P. Sheets,(unknown),Kevin Wilson,Nicolas Stransky,Jason D. Brubaker,Timothy J. Guzi,Nancy E. Kohl,Christoph Lengauer	10
3	Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi 2016 ·Toxicology Research ·Vilmos Csizmadia,Paul Hales,Christopher Tsu,Jingya Ma,(unknown),Pooja Shah,Paul Fleming,Joseph J. Senn,Vivek J. Kadambi,Lawrence R. Dick,Francis S. Wolenski	10
4	Abstract A164: The small molecule UAE inhibitor TAK-243 (MLN7243) prevents DNA damage repair and reduces cell viability/tumor growth when combined with radiation, carboplatin and docetaxel 2015 ·Molecular Cancer Therapeutics ·Michael A. Milhollen,(unknown),Tary Traore,Jessica J. Huck,Darshan S. Sappal,(unknown),Eric S. Lightcap,Yuko Ishii,Jeff Ciavarri,Paul Fleming,Neil Bence,Marc L. Hyer	2
5	561 Nonclinical characterization of the first in class investigational ubiquitin activating enzyme inhibitor MLN7243 in cellular and in vivo models of cancer in support of a phase I study 2014 ·European Journal of Cancer ·Michael A. Milhollen,Marc L. Hyer,Jeff Ciavarri,Tary Traore,Darshan S. Sappal,Jessica J. Huck,Jun Shi,James Duffy,(unknown),Jay Brownell,Yuanyou Yang,B. M. J. Stringer,(unknown),Erik Koenig,Anya Lublinsky,Robert Griffin,Chengcai Xia,(unknown),Paul Fleming,Neil Bence	1
6	Optimization of a series of dipeptides with a P3 β-neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome 2012 ·MedChemComm ·Christopher Blackburn,(unknown),Jonathan L. Blank,Frank J. Bruzzese,Nancy J. Bump,Lawrence R. Dick,Paul Fleming,Khristofer Garcia,Paul Hales,Matthew D. Jones,(unknown),(unknown),Darshan S. Sappal,Michael D. Sintchak,Christopher Tsu,Cindy Q. Xia,(unknown),Kenneth M. Gigstad	9
7	Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea 2011 ·Cancer Chemotherapy and Pharmacology ·Bret Bannerman,Ling Xu,Matthew D. Jones,Christopher Tsu,Jie Yu,Paul Hales,Johan Monbaliu,Paul Fleming,Lawrence R. Dick,Mark Manfredi,Christopher F. Claiborne,Joseph B. Bolen,Erik Kupperman,Allison Berger	32
8	Cellular and biochemical characterization of an inhibitor of the Ubiquitin Activating Enzyme (UAE) 2011 ·Darshan S. Sappal,Neil Bence,Paul Fleming,Michael A. Milhollen,Jessica Riceberg,Kara M. Hoar,(unknown),(unknown),(unknown),Trupti Lingaraj,David C. Bouck,Eric S. Lightcap,(unknown),Lawrence R. Dick,Petter O. Veiby,(unknown),Joseph B. Bolen	1
9	Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer 2010 ·Cancer Research ·Erik Kupperman,Edmund C. Lee,Yueying Cao,Bret Bannerman,Michael Fitzgerald,Allison Berger,Jie Yu,Yang Yu,Paul Hales,Frank J. Bruzzese,Jane Liu,Jonathan L. Blank,Khristofer Garcia,Christopher Tsu,Lawrence R. Dick,Paul Fleming,Li Yu,Mark Manfredi,Mark Rolfe,Joe Bolen	409
10	Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome 2010 ·Bioorganic & Medicinal Chemistry Letters ·Christopher Blackburn,(unknown),Jonathan L. Blank,Frank J. Bruzzese,Nancy J. Bump,Lawrence R. Dick,Paul Fleming,Khristofer Garcia,Paul Hales,Zhigen Hu,Matthew D. Jones,(unknown),Darshan S. Sappal,Michael D. Sintchak,Christopher Tsu,Kenneth M. Gigstad	39
11	Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy 2010 ·Drug Discovery Today ·Lawrence R. Dick,Paul Fleming	233
12	Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit 2010 ·Biochemical Journal ·Christopher Blackburn,Kenneth M. Gigstad,Paul Hales,Khristofer Garcia,Matthew D. Jones,Frank J. Bruzzese,(unknown),(unknown),Teresa A. Soucy,Darshan S. Sappal,Nancy J. Bump,Edward J. Olhava,Paul Fleming,Lawrence R. Dick,Christopher Tsu,Michael D. Sintchak,Jonathan L. Blank	129
13	In-Vitro and in-Vivo Evaluation of the Orally Active Proteasome Inhibitor MLN9708 in Hematological Models of Human Cancer. 2009 ·Blood ·Erik Kupperman,Edmund Lee,Yueying Cao,Bret Bannerman,Michael Fitzgerald,Allison Berger,Jie Yu,Julie Zhang,Paul Hales,Frank J. Bruzzese,Jane Liu,Jonathan L. Blank,Khristofer Garcia,Christopher Tsu,Lawrence R. Dick,Paul Fleming,Li Yu,Mark Manfredi,Mark Rolfe,Joseph B. Bolen	1
14	The synthesis and characterization of 8-methoxy-5′-deoxyadenosylcobalamin: a coenzyme B12 analog which, following Co–C bond homolysis, avoids cyclization of the 8-methoxy-5′-deoxyadenosyl radical 2002 ·Journal of Inorganic Biochemistry ·Kenneth M. Doll,Paul Fleming,Richard G. Finke	2
15	The coenzyme B12 derivative N1-methyl-5′-deoxyadenosylcobalamin: Synthesis, characterization, stability towards dimroth rearrangement, and Co–C thermolysis product and kinetic studies 1998 ·Journal of Inorganic Biochemistry ·Paul Fleming,Brian E. Daikh,Richard G. Finke	12
16	ChemInform Abstract: Parallel Synthesis of 3‐Aminoimidazo[1,2‐a]pyridines and ‐pyrazines by a New Three‐Component Condensation. 1998 ·ChemInform ·Christopher Blackburn,Bing Guan,Paul Fleming,Kazumi Shiosaki,(unknown)	2
17	Parallel synthesis of 3-aminoimidazo[1,2-a]pyridines and pyrazines by a new three-component condensation 1998 ·Tetrahedron Letters ·Christopher Blackburn,Bing Guan,Paul Fleming,Kazumi Shiosaki,(unknown)	304
18	Biosynthetic studies on taxol 1994 ·Pure and Applied Chemistry ·Paul Fleming,Heinz G. Floss,(unknown),Andrew R. Knaggs,Albert I. Lansing,Ulla Mocek,Kevin D. Walker	5
19	Biosynthesis of Taxoids. Mode of Attachment of the Taxol Side Chain 1994 ·Journal of the American Chemical Society ·Paul Fleming,Andrew R. Knaggs,(unknown),Ursula Mocek,Heinz G. Floss	28
20	Rare .alpha.-alkyl isomers of cobalamins: synthesis, characterization, and properties of two diastereomers of the .alpha.-alkylcobalamin, .alpha.-(2-oxo-1,3-dioxolan-4-yl)cobalamin 1991 ·Journal of the American Chemical Society ·Yun W. Alelyunas,Paul Fleming,Richard G. Finke,(unknown),Luigi G. Marzilli	24

About Paul Fleming

Paul Fleming is a scholar working on Oncology, Molecular Biology and Rheumatology, having authored 23 papers that have together received 1.4k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (10 papers), Peptidase Inhibition and Analysis (6 papers) and Cancer Treatment and Pharmacology (4 papers). The work is most often cited by research in Hematology (271 citations), Oncology (455 citations) and Molecular Biology (958 citations). Paul Fleming has collaborated with scholars based in United States, Japan and Norway. Frequent co-authors include Lawrence R. Dick, Christopher Blackburn, Bing Guan, Kazumi Shiosaki, Paul Hales, Christopher Tsu, Jonathan L. Blank, Khristofer Garcia, Frank J. Bruzzese and Heinz G. Floss. Their work appears in journals such as Journal of the American Chemical Society, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact